A phase II trial of VP-16, ifosfamide, cisplatin, vinblastine, and bleomycin in advanced germ-cell tumors

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 19, Issue 5, 1996, Pages 487-491

  Blanke, Charles ^a   Loehrer, Patrick J ^b   Nichols, Craig R ^b   Einhorn, Lawrence H ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bleomycin; Cisplatin; Germ cell tumor; Ifosfamide; Vinblastine; VP 16

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINBLASTINE;

ADULT; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; GASTROINTESTINAL TOXICITY; GERM CELL TUMOR; HALLUCINATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG TOXICITY; MALE; OTOTOXICITY; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; ETOPOSIDE; GERMINOMA; HUMANS; IFOSFAMIDE; MALE; PROGNOSIS; SURVIVAL RATE; VINBLASTINE;

EID: 0029834211     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199610000-00012     Document Type: Article

References (12)

1. Einhorn LH. Treatment of testicular cancer a new and improved model. J Clin Oncol 1990;8:1777-81.
2. Einhorn LH, Richie WU. Cancer of the testis. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology, 4th ed. Philadelphia: Lippincott, 1993;1126-1151.
3. Hainsworth JD, Greco FA. Testicular germ cell neoplasms. Am J Med 1993;75:817-32.
4. Nichols C, Williams S, Loehrer P, et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 1991;9:1163-72.
5. Loehrer PJ, Einhorn LH, Elson P, et al. Phase III study of cisplatin plus etoposide with either bleomycin or ifosfamide in advanced stage germ cell tumors: an intergroup trial. Proc Am Soc Clin Oncol 1993;12:261 (abstract).
6. 16B) in disseminated germ cell tumors: long term follow-up. Proc Am Soc Clin Onc 1992;11:196(abstract).
7. Droz JP, Pico JL, Biron P, et al. No evidence of a benefit of early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumors: preliminary results of a randomized trial. Proc Am Soc Clin Onc 1992;11:197(abstract).
8. Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987;316:1435-40.
9. Bosl GJ, Geller NL, Vogelzang NJ, et al. Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor- risk patients with germ cell tumors. J Clin Oncol 1987;5:436-40.
10. Motzer RJ, Cooper K, Geller ML, et al. Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors. Cancer 1990;65:2465-70.
11. Toner GC, Geller NL, Lin S-Y, et al. Extragonadal and poor- risk nonseminomatous germ cell tumors: survival and prognostic features. Cancer 1991;67:2049-57.
12. Nichols CR, Saxman S, Williams SD, et al. Primary mediastinal nonseminomatous germ cell tumors: a modern single institution experience. Cancer 1990;65:1641-6.